Table 2.
Summary of immunocomplexes formed between Actoxumab and TcdA and their fragments as determined by SEC-MALLS
Antibody | Antigen | Molar ratio (Antibody:antigen) | MW of complex (kDa) | Putative stoichiometry (Antibody:antigen) |
---|---|---|---|---|
Actoxumab | – | – | 146 | 1:0 |
Fab | – | – | 47 | 1:0 |
– | TcdA | – | 296 | 0:1 |
– | A1 | – | 100 | 0:1 |
Actoxumab | TcdA | 1:1 | 2141 | 5:4 |
5:1 | 2090 | 5:4 | ||
Actoxumab | A1 | 1:5 | 359 | 1:2 |
1:1 | 394 | 2:1 | ||
2:1 | 653 | 3:2 or 4:1 | ||
5:1 | 1453 | 6:5, 7:4, or 8:3 | ||
Fab | TcdA | 1:5 | 324 | 1:1 |
1:1 | 358 | 1:1 or 2:1 | ||
5:1 | 389 | 2:1 | ||
10:1 | 393 | 2:1 |